DAF
0.018
80%
ATC
0.001
-50%
FAU
0.009
50%
ARV
0.003
-25%
DXN
0.4
45.5%
RWL
0.15
-21.1%
ACU
0.15
42.9%
CHM
0.016
-20%
C7A
0.004
33.3%
ERE
0.012
-20%
M2M
0.008
33.3%
SP3
0.009
-18.2%
NXL
1.832
28.6%
KGN
3.72
-17.5%
AXN
0.033
22.2%
CDE
0.005
-16.7%
AUQ
0.045
21.6%
ENL
0.005
-16.7%
RRE
0.11
20.9%
RLG
0.005
-16.7%
AEU
0.555
20.7%
CRR
0.006
-14.3%
COY
0.006
20%
RFT
0.006
-14.3%
WRX
0.024
20%
UNT
0.006
-14.3%
CTO
0.014
16.7%
LML
0.007
-12.5%
ESR
0.035
16.7%
EPI
0.405
-12%
M4M
0.007
16.7%
DTZ
0.023
-11.5%
WSR
0.007
16.7%
PCL
0.008
-11.1%
LOT
0.277
15.4%
SNS
0.032
-11.1%
EUR
0.352
15.4%
KRR
0.076
-10.6%
LEX
0.15
15.4%
BDX
0.052
-10.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT U.S. FDA accepted new drug application

Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX